Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CBC China Life Science Infrastructure Fund Holds First Close with $500 Million

publication date: Nov 18, 2021

CBC Group announced its CBC China Life Science Infrastructure Venture (CLSIV) fund held a first close of $500 million with a hard cap of $1.5 billion in total equity. The fund was formed to provide best-in-class facilities for life science research, manufacturing and support services in China. CBC Group, which claims to be Asia's largest healthcare-dedicated investment firm, formed a partnership with the Netherlands' APG Asset Management to sponsor the CBC Healthcare Infrastructure Platform (CBC HIP), which includes the China-focused life science infrastructure fund as one of its offerings. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital